299660.KQ
Cellid, Co., Ltd. [299660.KQ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
299660.KQ Stock Summary
Top 10 Correlated Stocks
299660.KQ
In the News
299660.KQ Financial details
Company Rating
-
Market Cap
55.09B
Income
-11.61B
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
64
Optionable
No
Shortable
Yes
Earnings
19 Mar 2019
P/E
-2.14
Forward P/E
-
PEG
0.43
P/S
92.25
P/B
2.92
P/C
-
P/FCF
-
Quick Ratio
0.29
Current Ratio
0.68
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.08K
EPS next Y
-
EPS next Q
-
EPS this Y
-49.65%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-67.46%
-
-
-
-
SMA20
-0.03%
SMA50
-23.99%
SMA100
-39.77%
Inst Own
-
Inst Trans
-
ROA
-68%
ROE
-101%
ROC
-0.7%
Gross Margin
31%
Oper. Margin
-2712%
Profit Margin
-4380%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3100.0-11950.0
52W High
-70.38%
52W Low
+14.19%
RSI
49
Rel Volume
2.3
Avg Volume
70.4K
Volume
161.7K
Perf Week
-4.84%
Perf Month
0.43%
Perf Quarter
-19.73%
Perf Half Y
-28.12%
-
-
-
-
Beta
1.549
-
-
Volatility
76.71%, 172.87%
Prev Close
0%
Price
3540
Change
0.85%
Company Profile
- Volume Average 70.4K
- Market Capitalization 55.09B
- Employee 64
- CEO Yuil Kang Chang
- Headquarters Seoul,KR
- IPO Date 2019-02-19
-
Website
http://www.cellid.co.kr 
Cellid, Inc. develops immunothetherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and genital cancer with human papilloma virus antigen; BVAC-B for gastric, ovarian, lung, and pancreatic cancer with HER-2/neu antigen; and BVAC-P for prostate, urinary tract, and brain cancer with PAP/PSMA antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; and BVAC-Neo, a customized immunotherapeutic vaccine. Cellid, Inc. was founded in 2006 and is based in Seoul, South Korea.
